The company has yet to file a prospectus for the IPO. If the IPO goes according to plan, it could result in a valuation of $600 million for EndoChoice, according to the report.
More articles on gastroenterology:
To survive in GI, be prepared
Do gastroenterologists underestimate IBD severity?
15 gastroenterologists making headlines this month
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
